Boehringer Ingelheim and BioMed X team up for COPD project

Boehringer Ingelheim and BioMed X have successfully applied a crowdsourcing approach to establish a research team of outstanding scientists from around the world who will endeavour to identify new approaches for the treatment of patients with chronic obstructive pulmonary disease (COPD).

COPD is a chronic, progressive, treatable but incurable lung disease affecting 210 million people worldwide. It is a growing world health priority and is predicted to become the 3rd leading cause of death by 2030.

The interdisciplinary team will focus on the characterisation of epigenetic regulators driving hallmarks of the COPD pathophysiology, as recent evidence indicates that epigenetic mechanisms could be major drivers of this devastating disease. Epigenetics is defined as heritable changes in gene expression or phenotype that do not involve a change in the underlying DNA sequence, Renata Jurkowska will head the research team that will be established in the BioMed X Innovation Centre located on the campus of the University of Heidelberg, Germany.

Project could accelerate the discovery of new medicines for treating patients with COPD

Christian Tidona, founder and Managing Director of BioMed X, explained, “The newly formed research team will build on our strong scientific networks in Heidelberg and the Biotech Cluster Rhine-Neckar. The team will be guided by experienced mentors from academia and Boehringer Ingelheim and will receive an intensive entrepreneurship and leadership training.”

Michel Pairet, Senior Corporate Vice President of Research and Non-clinical Development at Boehringer Ingelheim said, “We are very enthusiastic about working with this highly motivated team of talented scientists at the BioMed X Innovation Centre. We firmly believe that crowd sourcing is an exciting and refreshing way to find unconventional solutions based on the diversity of talents and ideas. This project is ideally suited to integrate breakthrough science in epigenetics research and emerging insights into the pathophysiology of COPD. Understanding epigenetic mechanisms will allow us to discover unknown drivers of the disease and accelerate the discovery of new medicines for treating patients with COPD.”

The research team will be sponsored by Boehringer Ingelheim for two years with the option to extend the funding period up to a total of four years.